EQUITY (Tables)

3 Months Ended

Mar. 31, 2026

Investments, Debt and Equity Securities [Abstract]

SCHEDULE OF CHANGES IN FAIR VALUE OF MARKETABLE SECURITIES

The table below sets forth a summary of the changes in the fair value of the Company’s marketable securities for the three-month periods ended March 31, 2026, and 2025:

	Three months ended March 31,
	2026			2025
	($ in thousands)
Balance at beginning of the period	$	45,272		$	15,721
Additions		-			6,909
Maturity		(15,000	)		(9,000	)
Interest Received		(378	)		(69	)
Changes in fair value during the period		314			142
Balance at end of the period		30,208			13,703

SCHEDULE OF ISSUANCE OF WARRANTS TO PURCHASE COMMON STOCK

	Number of underlying Common stock		Exercise price		Expiration date
Series J Warrants		12,914,086		1.3827		*
Series K Warrants		12,914,078		1.3827		*
Total Warrants		25,828,164

* The Series J Warrants and Series K Warrants have a term of the earlier of (i) May 15, 2028 and (ii) (A) in the case of the Series J Warrants, 20 trading days following the Company’s announcement of receipt of FDA approval for the SwitchGuard and CGuard Prime 80 cm and (B) in the case on the Series K Warrants, 20 trading days following the end of the fourth fiscal quarter after the fiscal quarter in which the first commercial sales of CGuard Prime in the U.S. begins. Following the commencement of the first commercial sales of CGuard Prime in the United States, which occurred during the third fiscal quarter of 2025 in July 2025, the Series K Warrants are scheduled to expire twenty (20) trading days after the end of the fourth fiscal quarter thereafter, which is October 28, 2026.